JP6011543B2 - 糖尿病、肥満および関連疾患の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン - Google Patents
糖尿病、肥満および関連疾患の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン Download PDFInfo
- Publication number
- JP6011543B2 JP6011543B2 JP2013543816A JP2013543816A JP6011543B2 JP 6011543 B2 JP6011543 B2 JP 6011543B2 JP 2013543816 A JP2013543816 A JP 2013543816A JP 2013543816 A JP2013543816 A JP 2013543816A JP 6011543 B2 JP6011543 B2 JP 6011543B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- piperidine
- dihydro
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DHSVJKQZMXUZPB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C)(C1)Oc(cn2)c1cc2Cl)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C)(C1)Oc(cn2)c1cc2Cl)=O DHSVJKQZMXUZPB-UHFFFAOYSA-N 0.000 description 1
- UIZVKQNUGBSIGA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C)(C1)Oc2c1cc(-c1ccc(CS(C)(=O)=O)cc1F)nc2)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C)(C1)Oc2c1cc(-c1ccc(CS(C)(=O)=O)cc1F)nc2)=O UIZVKQNUGBSIGA-UHFFFAOYSA-N 0.000 description 1
- ICOQDFXFLUFJSG-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C1)Oc(cc2)c1cc2Br)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C1)Oc(cc2)c1cc2Br)=O ICOQDFXFLUFJSG-UHFFFAOYSA-N 0.000 description 1
- SIFJASGBCRJHRJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C1)Oc2c1cc(-c(c(F)c1)ccc1S(C)(=O)=O)nc2)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C1)Oc2c1cc(-c(c(F)c1)ccc1S(C)(=O)=O)nc2)=O SIFJASGBCRJHRJ-UHFFFAOYSA-N 0.000 description 1
- MNSTXTCYFOYKAE-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C1)Oc2c1cc(-c1cnc[o]1)nc2)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C1)Oc2c1cc(-c1cnc[o]1)nc2)=O MNSTXTCYFOYKAE-UHFFFAOYSA-N 0.000 description 1
- ZLLIBFJKXXPAQT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(Cc1c2)Oc1cnc2-[n]1cncc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(Cc1c2)Oc1cnc2-[n]1cncc1)=O ZLLIBFJKXXPAQT-UHFFFAOYSA-N 0.000 description 1
- JGVNAKKLHCGAMA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c1cc(cc(-c(c(F)c2)ccc2S(C)(=O)=O)nc2)c2[o]1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c1cc(cc(-c(c(F)c2)ccc2S(C)(=O)=O)nc2)c2[o]1)=O JGVNAKKLHCGAMA-UHFFFAOYSA-N 0.000 description 1
- JHAUMLNWDJJAAD-UHFFFAOYSA-N CC(C)OC(N(CC1)CCC1C(C1)Oc(cc2)c1cc2-c(nc1)ccc1S(C)(=O)=O)=O Chemical compound CC(C)OC(N(CC1)CCC1C(C1)Oc(cc2)c1cc2-c(nc1)ccc1S(C)(=O)=O)=O JHAUMLNWDJJAAD-UHFFFAOYSA-N 0.000 description 1
- VMVOYOJAZRDMGM-UHFFFAOYSA-N CC(C)OC(N(CC1)CCC1C(C1)Oc(cc2)c1cc2-c1ccc(NC(C)=O)nn1)=O Chemical compound CC(C)OC(N(CC1)CCC1C(C1)Oc(cc2)c1cc2-c1ccc(NC(C)=O)nn1)=O VMVOYOJAZRDMGM-UHFFFAOYSA-N 0.000 description 1
- BOSVWISOESDXBE-UHFFFAOYSA-N CC(C)OC(N(CC1)CCC1C(C1)Oc2c1cc(C(CC1)=CCN1S(C)(=O)=O)nc2)=O Chemical compound CC(C)OC(N(CC1)CCC1C(C1)Oc2c1cc(C(CC1)=CCN1S(C)(=O)=O)nc2)=O BOSVWISOESDXBE-UHFFFAOYSA-N 0.000 description 1
- KPKVTYDGJLWILC-UHFFFAOYSA-N CC(C1)(C2CCNCC2)Oc2c1cc(-c(cc1)ccc1[SH2+2]C)nc2 Chemical compound CC(C1)(C2CCNCC2)Oc2c1cc(-c(cc1)ccc1[SH2+2]C)nc2 KPKVTYDGJLWILC-UHFFFAOYSA-N 0.000 description 1
- MUIOFFJMRCFAGL-UHFFFAOYSA-N CC1(CC1)OC(N(CC1)CCC1C(C1)Oc2c1cc(C(CC1)=CCN1S(C)(=O)=O)nc2)=O Chemical compound CC1(CC1)OC(N(CC1)CCC1C(C1)Oc2c1cc(C(CC1)=CCN1S(C)(=O)=O)nc2)=O MUIOFFJMRCFAGL-UHFFFAOYSA-N 0.000 description 1
- YOPPCFMQXJTPOZ-VWLOTQADSA-N CC1(CC1)OC(N(CC1)CCC1[C@](C)(C1)Oc2c1cc(-c(cc1)ccc1S(C)(=O)=O)nc2)=O Chemical compound CC1(CC1)OC(N(CC1)CCC1[C@](C)(C1)Oc2c1cc(-c(cc1)ccc1S(C)(=O)=O)nc2)=O YOPPCFMQXJTPOZ-VWLOTQADSA-N 0.000 description 1
- KEPJWNVAQRQSSA-UHFFFAOYSA-N CS(Cc(cc1)ccc1-c(nc1)cc(C2)c1OC2C(CC1)CCN1C(OC1CCC1)=O)(=O)=O Chemical compound CS(Cc(cc1)ccc1-c(nc1)cc(C2)c1OC2C(CC1)CCN1C(OC1CCC1)=O)(=O)=O KEPJWNVAQRQSSA-UHFFFAOYSA-N 0.000 description 1
- WSJHKZQZBBLRRG-UHFFFAOYSA-N CS(c(cc1)ccc1-c(nc1)cc(C2)c1OC2C1CCNCC1)(=O)=O Chemical compound CS(c(cc1)ccc1-c(nc1)cc(C2)c1OC2C1CCNCC1)(=O)=O WSJHKZQZBBLRRG-UHFFFAOYSA-N 0.000 description 1
- JPNDTPNCYOHHFX-UHFFFAOYSA-N Cc(cc(c(C#N)c1)F)c1F Chemical compound Cc(cc(c(C#N)c1)F)c1F JPNDTPNCYOHHFX-UHFFFAOYSA-N 0.000 description 1
- OKDUYWXZUOTFAI-UHFFFAOYSA-N Cc(cc1)c(C)cc1S(C)(=O)=O Chemical compound Cc(cc1)c(C)cc1S(C)(=O)=O OKDUYWXZUOTFAI-UHFFFAOYSA-N 0.000 description 1
- VCZNNAKNUVJVGX-UHFFFAOYSA-N Cc(cc1)ccc1C#N Chemical compound Cc(cc1)ccc1C#N VCZNNAKNUVJVGX-UHFFFAOYSA-N 0.000 description 1
- YYDNBUBMBZRNQQ-UHFFFAOYSA-N Cc(cc1)ccc1S(C)(=O)=O Chemical compound Cc(cc1)ccc1S(C)(=O)=O YYDNBUBMBZRNQQ-UHFFFAOYSA-N 0.000 description 1
- JXSMDKCYNPJOFK-UHFFFAOYSA-N Cc(cc1)cnc1S(C)(=O)=O Chemical compound Cc(cc1)cnc1S(C)(=O)=O JXSMDKCYNPJOFK-UHFFFAOYSA-N 0.000 description 1
- WCGNLBCJPBKXCN-UHFFFAOYSA-N Cc(cc1F)ccc1C#N Chemical compound Cc(cc1F)ccc1C#N WCGNLBCJPBKXCN-UHFFFAOYSA-N 0.000 description 1
- GHLKMUFOKGPMRY-UHFFFAOYSA-N Cc(cc1F)ccc1S(C)(=O)=O Chemical compound Cc(cc1F)ccc1S(C)(=O)=O GHLKMUFOKGPMRY-UHFFFAOYSA-N 0.000 description 1
- KUQQONVKIURIQU-UHFFFAOYSA-N Cc(ccc(C#N)c1)c1F Chemical compound Cc(ccc(C#N)c1)c1F KUQQONVKIURIQU-UHFFFAOYSA-N 0.000 description 1
- JVSGZPNRSFBICJ-UHFFFAOYSA-N Cc(ccc(S(C)(=O)=O)c1)c1F Chemical compound Cc(ccc(S(C)(=O)=O)c1)c1F JVSGZPNRSFBICJ-UHFFFAOYSA-N 0.000 description 1
- GHUZKFWDASVPEO-UHFFFAOYSA-N Cc(nc1)ccc1S(C)(=O)=O Chemical compound Cc(nc1)ccc1S(C)(=O)=O GHUZKFWDASVPEO-UHFFFAOYSA-N 0.000 description 1
- SEJKMIGLIXGOFY-UHFFFAOYSA-N Cc1c(C)ncc(S(C)(=O)=O)c1 Chemical compound Cc1c(C)ncc(S(C)(=O)=O)c1 SEJKMIGLIXGOFY-UHFFFAOYSA-N 0.000 description 1
- AIKUBOPKWKZULG-UHFFFAOYSA-N Cc1ccnnc1 Chemical compound Cc1ccnnc1 AIKUBOPKWKZULG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10195814 | 2010-12-17 | ||
| EP10195814.8 | 2010-12-17 | ||
| PCT/EP2011/073067 WO2012080476A1 (en) | 2010-12-17 | 2011-12-16 | Fused dihydropyrans as gpr119 modulators for the treatment of diabetes, obesity and related diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013545791A JP2013545791A (ja) | 2013-12-26 |
| JP2013545791A5 JP2013545791A5 (enExample) | 2015-02-05 |
| JP6011543B2 true JP6011543B2 (ja) | 2016-10-19 |
Family
ID=45470522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543816A Active JP6011543B2 (ja) | 2010-12-17 | 2011-12-16 | 糖尿病、肥満および関連疾患の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8669271B2 (enExample) |
| EP (1) | EP2651931B1 (enExample) |
| JP (1) | JP6011543B2 (enExample) |
| AR (1) | AR084349A1 (enExample) |
| UY (1) | UY33805A (enExample) |
| WO (1) | WO2012080476A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| EP2665719B1 (en) * | 2011-01-21 | 2016-05-04 | Boehringer Ingelheim International GmbH | Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders |
| US8822471B2 (en) | 2011-03-14 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| WO2012170867A1 (en) * | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| WO2012168315A1 (en) | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
| US8853239B2 (en) * | 2011-12-09 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| US9012456B2 (en) * | 2012-02-28 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| US8809361B2 (en) * | 2012-05-07 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 2,3-dihydrofuro[2,3-c]pyridines, their use as modulators of the G-protein-coupled receptor GPR119 and pharmaceutical compositions thereof |
| WO2013186109A1 (en) * | 2012-06-12 | 2013-12-19 | Boehringer Ingelheim International Gmbh | 2,3-dihydro-furo[2,3-c]pyridin-2-yl-piperidine derivatives, pharmaceutical compositions containing them and uses thereof |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| WO2014167009A1 (en) | 2013-04-12 | 2014-10-16 | Bayer Cropscience Ag | Novel triazole derivatives |
| EP2984080B1 (en) | 2013-04-12 | 2017-08-30 | Bayer CropScience Aktiengesellschaft | Novel triazolinthione derivatives |
| EA030024B1 (ru) | 2013-04-12 | 2018-06-29 | Байер Кропсайенс Акциенгезельшафт | Новые производные триазола для борьбы с фитопатогенными вредоносными грибами |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| US9493450B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| BR112017021109A2 (pt) | 2015-04-02 | 2018-07-03 | Bayer Cropscience Ag | derivados de triazol como fungicidas |
| PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| US10208030B2 (en) | 2016-04-08 | 2019-02-19 | Mankind Pharma Ltd. | GPR119 agonist compounds |
| US10954229B2 (en) | 2016-04-08 | 2021-03-23 | Mankind Pharma Ltd. | GPR119 agonist compounds |
| US10526345B2 (en) * | 2016-04-08 | 2020-01-07 | Mankind Pharma Ltd. | Compounds as GPR119 agonists |
| CN109414410B (zh) | 2016-04-22 | 2022-08-12 | 因赛特公司 | Lsd1抑制剂的制剂 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090221644A1 (en) * | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| CA2661371A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyrimidine compounds for treating gpr119 related disorders |
| BRPI0719941A2 (pt) * | 2006-12-06 | 2014-04-22 | Smithkline Beecham Corp | Composto, uso de um composto, método para o tratamento de distúrbios ou condições metabólicos, composição farmacêutica, e, processo para a preparação de uma composição farmacêutica |
| PE20090213A1 (es) * | 2007-05-04 | 2009-02-28 | Bristol Myers Squibb Co | Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos |
| WO2008137435A1 (en) * | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| AU2008302570B2 (en) * | 2007-09-20 | 2012-05-31 | Irm Llc | Compounds and compositions as modulators of GPR119 activity |
| WO2009106565A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Agonists of gpr119 |
| WO2009150144A1 (en) * | 2008-06-10 | 2009-12-17 | Inovacia Ab | New gpr119modulators |
| JPWO2010084944A1 (ja) * | 2009-01-22 | 2012-07-19 | 田辺三菱製薬株式会社 | 新規ピロロ［２，３−ｄ］ピリミジン化合物 |
| EP2399914A4 (en) * | 2009-02-18 | 2012-08-29 | Takeda Pharmaceutical | FUSED HETEROCYCLIC CORE COMPOUND |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011140161A1 (en) * | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| JP5794297B2 (ja) | 2010-05-07 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｐｒ１１９アゴニストとしてのピリダジノン |
| UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| EP2665719B1 (en) | 2011-01-21 | 2016-05-04 | Boehringer Ingelheim International GmbH | Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders |
| US8822471B2 (en) | 2011-03-14 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
-
2011
- 2011-12-15 UY UY0001033805A patent/UY33805A/es not_active Application Discontinuation
- 2011-12-16 US US13/327,823 patent/US8669271B2/en active Active
- 2011-12-16 WO PCT/EP2011/073067 patent/WO2012080476A1/en not_active Ceased
- 2011-12-16 JP JP2013543816A patent/JP6011543B2/ja active Active
- 2011-12-16 AR ARP110104756A patent/AR084349A1/es unknown
- 2011-12-16 EP EP11807666.0A patent/EP2651931B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013545791A (ja) | 2013-12-26 |
| UY33805A (es) | 2012-07-31 |
| EP2651931A1 (en) | 2013-10-23 |
| WO2012080476A1 (en) | 2012-06-21 |
| US8669271B2 (en) | 2014-03-11 |
| AR084349A1 (es) | 2013-05-08 |
| US20120322784A1 (en) | 2012-12-20 |
| EP2651931B1 (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6011543B2 (ja) | 糖尿病、肥満および関連疾患の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン | |
| JP5703393B2 (ja) | 糖尿病、肥満および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン | |
| JP5935154B2 (ja) | Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド | |
| JP6094578B2 (ja) | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン | |
| WO2011093501A1 (ja) | Ｇｐｒ１１９作動薬 | |
| JP6066126B2 (ja) | 新規化合物、医薬組成物及びその使用 | |
| JP6136032B2 (ja) | 新規な２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン、Ｇタンパク質共役受容体ＧＰＲ１１９のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物 | |
| JP6263789B2 (ja) | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 | |
| JP6119088B2 (ja) | ２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン−２−イル−ピペリジン誘導体、それらを含む医薬組成物及びその使用 | |
| JP6119081B2 (ja) | Ｇｐｒ１１９に対するフロ［２，３−ｃ］ピリジン活性物質 | |
| TW201305144A (zh) | 新穎化合物、醫藥組合物及其用途 | |
| JP2015523404A (ja) | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 | |
| OA16478A (en) | Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders. | |
| TW201249837A (en) | New compounds, pharmaceutical compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141212 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150806 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160804 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160829 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160905 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6011543 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |